Peptide Library

Human study PLS-00132

Thymosins: structure, function and therapeutic applications.

Other design · Not reported participants enrolled · not included in the assessments (not human)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Thymosins: structure, function and therapeutic applications.primary · Thymus · 1984-01-01 · PMID 6087503

Design and participants

Design
Other design
Population
Not reported
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
Research Support, U.S. Gov't, P.H.S. and Research Support, Non-U.S. Gov't (PubMed publication types); no further details in the record.

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Thymosin fraction 5 corrects immune deficiencies in animals and humans. Several active peptides, including alpha 1 and beta 4, have been isolated. Preliminary results of NCI trials of fraction 5 and alpha 1 look encouraging.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Human trials described used thymosin fraction 5 and thymosin alpha 1, not thymosin beta 4.
    • abstract only: Only the abstract is available in the record; no methods or data are reported.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • arms: PMID 6087503, abstract (sentences 5-6 (trials used fraction 5 and alpha 1)) · extracted by AI (automated, not verified by a person) · abstract only
    • author_conclusion: PMID 6087503, abstract (sentences 1 and 7) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 6087503, abstract (sentences 1-7 (overview of thymosin research and trials)) · extracted by AI (automated, not verified by a person) · abstract only
    • funding: PMID 6087503, title (PubMed publication types) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).